
# World Journal of *Clinical Cases*

World J Clin Cases 2022 April 16; 10(11): 3321-3638





Published by Baishideng Publishing Group Inc

W J C C World Journal of Clinical Cases

#### Contents

#### Thrice Monthly Volume 10 Number 11 April 16, 2022

#### **REVIEW**

3321 Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma Yao M, Yang JL, Wang DF, Wang L, Chen Y, Yao DF

#### **ORIGINAL ARTICLE**

#### **Clinical and Translational Research**

Autophagy-related long non-coding RNA prognostic model predicts prognosis and survival of melanoma 3334 patients

Qiu Y, Wang HT, Zheng XF, Huang X, Meng JZ, Huang JP, Wen ZP, Yao J

3352 Identification of circ\_0000375 and circ\_0011536 as novel diagnostic biomarkers of colorectal cancer Yin TF, Du SY, Zhao DY, Sun XZ, Zhou YC, Wang QQ, Zhou GYJ, Yao SK

#### **Retrospective Study**

3369 Echocardiography in the diagnosis of Shone's complex and analysis of the causes for missed diagnosis and misdiagnosis

Li YD, Meng H, Pang KJ, Li MZ, Xu N, Wang H, Li SJ, Yan J

- Predictors and prognostic impact of post-operative atrial fibrillation in patients with hip fracture surgery 3379 Bae SJ, Kwon CH, Kim TY, Chang H, Kim BS, Kim SH, Kim HJ
- 3389 Added value of systemic inflammation markers for monitoring response to neoadjuvant chemotherapy in breast cancer patients

Ke ZR, Chen W, Li MX, Wu S, Jin LT, Wang TJ

3401 Washed microbiota transplantation reduces serum uric acid levels in patients with hyperuricaemia Cai JR, Chen XW, He YJ, Wu B, Zhang M, Wu LH

#### **Clinical Trials Study**

Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head 3414 and neck squamous cell carcinoma

Huo RX, Jin YY, Zhuo YX, Ji XT, Cui Y, Wu XJ, Wang YJ, Zhang L, Zhang WH, Cai YM, Zheng CC, Cui RX, Wang QY, Sun Z, Wang FW

#### **META-ANALYSIS**

3426 Effect of enhanced recovery after surgery on inflammatory bowel disease surgery: A meta-analysis Peng D, Cheng YX, Tao W, Tang H, Ji GY

Accuracy of ultrasound elastography for predicting breast cancer response to neoadjuvant chemotherapy: 3436 A systematic review and meta-analysis

Chen W, Fang LX, Chen HL, Zheng JH



Combon	World Journal of Clinical Cases Contents Thrice Monthly Volume 10 Number 11 April 16, 2022	
Conten		
3449	Association of chronic obstructive pulmonary disease with mild cognitive impairment and dementia risk: A systematic review and meta-analysis	
	Zhao LY, Zhou XL	
	CASE REPORT	
3461	Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report	
	Yuan F, Liu N, Yang MZ, Zhang XT, Luo H, Zhou H	
3472	Difference and similarity between type A interrupted aortic arch and aortic coarctation in adults: Two case reports	
	Ren SX, Zhang Q, Li PP, Wang XD	
3478	Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer: A case report	
	Huang KK, Han SS, He LY, Yang LL, Liang BY, Zhen QY, Zhu ZB, Zhang CY, Li HY, Lin Y	
3485	Unusual glomus tumor of the lower leg: A case report	
	Wang HY, Duan P, Chen H, Pan ZY	
3490	Pulmonary <i>Cladosporium</i> infection coexisting with subcutaneous <i>Corynespora cassiicola</i> infection in a patient: A case report	
	Wang WY, Luo HB, Hu JQ, Hong HH	
3496	Preoperational diagnosis and management of breast ductal carcinoma <i>in situ</i> arising within fibroadenoma: Two case reports	
	Wu J, Sun KW, Mo QP, Yang ZR, Chen Y, Zhong MC	
3505	Reconstruction of complex chest wall defects: A case report	
	Huang SC, Chen CY, Qiu P, Yan ZM, Chen WZ, Liang ZZ, Luo KW, Li JW, Zhang YQ, Huang BY	
3511	Young children with multidrug-resistant epilepsy and vagus nerve stimulation responding to perampanel: A case report	
	Yang H, Yu D	
3518	Intramedullary nailing for pathological fractures of the proximal humerus caused by multiple myeloma: A case report and review of literature	
	Xu GQ, Wang G, Bai XD, Wang XJ	
3527	Double tracheal stents reduce side effects of progression of malignant tracheoesophageal fistula treated with immunotherapy: A case report	
	Li CA, Yu WX, Wang LY, Zou H, Ban CJ, Wang HW	
3533	Ankylosing spondylitis complicated with andersson lesion in the lower cervical spine: A case report	
	Peng YJ, Zhou Z, Wang QL, Liu XF, Yan J	
3541	Severe gastric insufflation and consequent atelectasis caused by gas leakage using AIR-Q laryngeal mask airway: A case report	
	Zhao Y. Li P. Li DW. Zhao GF. Li XY	



World Journal of Clinical Cases					
Conter	its Thrice Monthly Volume 10 Number 11 April 16, 2022				
3547	Hypereosinophilic syndrome presenting as acute ischemic stroke, myocardial infarction, and arterial involvement: A case report				
	Sun RR, Chen TZ, Meng M				
3553	Cytochrome P450 family 17 subfamily A member 1 mutation causes severe pseudohermaphroditism: A case report				
	Gong Y, Qin F, Li WJ, Li LY, He P, Zhou XJ				
3561	Patellar dislocation following distal femoral replacement after extra-articular knee resection for bone sarcoma: A case report				
	Kubota Y, Tanaka K, Hirakawa M, Iwasaki T, Kawano M, Itonaga I, Tsumura H				
3573	Qingchang decoction retention enema may induce clinical and mucosal remission in left-sided ulcerative colitis: A case report				
	Li PH, Tang Y, Wen HZ				
3579	Anti-nuclear matrix protein 2+ juvenile dermatomyositis with severe skin ulcer and infection: A case report and literature review				
	Wang YT, Zhang Y, Tang T, Luo C, Liu MY, Xu L, Wang L, Tang XM				
3587	Ultrasound-guided local ethanol injection for fertility-preserving cervical pregnancy accompanied by fetal heartbeat: Two case reports				
	Kakinuma T, Kakinuma K, Matsuda Y, Ohwada M, Yanagida K, Kaijima H				
3593	Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report				
	Wei HP, Mao J, Hu ZL				
3601	Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report				
	Liang HP, Luo XC, Zhang YL, Liu B				
3609	Papillary thyroid microcarcinoma with contralateral lymphatic skip metastasis and breast cancer: A case report				
	Ding M, Kong YH, Gu JH, Xie RL, Fei J				
3615	Contrast-enhanced ultrasound manifestations of synchronous combined hepatocellular- cholangiocarcinoma and hepatocellular carcinoma: A case report				
	Gao L, Huang JY, Lu ZJ, Lu Q				
3624	Thyrotoxicosis after a massive levothyroxine ingestion: A case report				
	Du F, Liu SW, Yang H, Duan RX, Ren WX				
3630	Pleomorphic adenoma of the left lacrimal gland recurred and transformed into myoepithelial carcinoma after multiple operations: A case report				
	Huang WP, Li LM, Gao JB				



### Contents

Thrice Monthly Volume 10 Number 11 April 16, 2022

#### **ABOUT COVER**

Editorial Board Member of World Journal of Clinical Cases, Chi-Yuan Yeh, MD, PhD, Assistant Professor, Chief Doctor, radiation oncology, Tungs' Taichung MetroHarbor Hospital, Taichung 43503, Taiwan. peteryeh46@gmail.com

#### **AIMS AND SCOPE**

The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

#### **INDEXING/ABSTRACTING**

The WJCC is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2021 Edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJCC as 1.337; IF without journal self cites: 1.301; 5-year IF: 1.742; Journal Citation Indicator: 0.33; Ranking: 119 among 169 journals in medicine, general and internal; and Quartile category: Q3. The WJCC's CiteScore for 2020 is 0.8 and Scopus CiteScore rank 2020: General Medicine is 493/793.

#### **RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Hua-Ge Yn; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS
World Journal of Clinical Cases	https://www.wjgnet.com/bpg/gerinfo/204
ISSN	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 2307-8960 (online)	https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
April 16, 2013	https://www.wignet.com/bpg/gerinfo/240
FREQUENCY Thrice Monthly	PUBLICATION ETHICS https://www.wjgnet.com/bpg/GerInfo/288
<b>EDITORS-IN-CHIEF</b> Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku	PUBLICATION MISCONDUCT https://www.wignet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/2307-8960/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE April 16, 2022	STEPS FOR SUBMITTING MANUSCRIPTS https://www.wignet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2022 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



World Journal of Clinical Cases

Submit a Manuscript: https://www.f6publishing.com

World J Clin Cases 2022 April 16; 10(11): 3426-3435

DOI: 10.12998/wjcc.v10.i11.3426

ISSN 2307-8960 (online)

META-ANALYSIS

# Effect of enhanced recovery after surgery on inflammatory bowel disease surgery: A meta-analysis

Dong Peng, Yu-Xi Cheng, Wei Tao, Hua Tang, Guang-Yan Ji

Specialty type: Gastroenterology and hepatology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

#### Peer-review report's scientific quality classification

Grade A (Excellent): A Grade B (Very good): 0 Grade C (Good): 0 Grade D (Fair): 0 Grade E (Poor): 0

P-Reviewer: Surlin VM, Romania

Received: August 20, 2021 Peer-review started: August 20, 2021

First decision: November 11, 2021 Revised: November 12, 2021 Accepted: February 27, 2022 Article in press: February 27, 2022 Published online: April 16, 2022



Dong Peng, Yu-Xi Cheng, Wei Tao, Hua Tang, Guang-Yan Ji, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

Corresponding author: Guang-Yan Ji, PhD, Doctor, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, No.1 Youyi Road, Yuanjiagang District, Chongqing 400016, China. jiguangyan168@163.com

## Abstract

#### BACKGROUND

The purpose of enhanced recovery after surgery (ERAS) was to reduce surgical pressure and accelerate postoperative functional recovery. Although the application of biologics in treating inflammatory bowel disease (IBD) has changed treatment strategies, most patients with IBD still require surgery.

#### AIM

To evaluate the advantage of ERAS in IBD surgery.

#### **METHODS**

The PubMed, EMBASE and Cochrane Library databases were searched from inception to March 21, 2021 to find eligible studies. The primary outcome was postoperative complications, and the secondary outcomes included operation time, time to first flatus, time to bowel movement, postoperative hospital stay and readmission. The PROSPERO registration ID of this meta-analysis is CRD42021238052.

#### RESULTS

A total of eight studies involving 1939 patients were included in this metaanalysis. There were no differences in baseline information between the ERAS group and the non-ERAS group. After pooling up all of the data, no significant difference was found between the ERAS group and the non-ERAS group in terms of postoperative overall complications [odds ratio = 0.82, 95% confidence interval (CI) = 0.66 to 1.02, P = 0.08]. The ERAS group had a lower prevalence of anastomotic fistula (odds ratio = 0.36, 95%CI = 0.13 to 0.95, P = 0.04), less time to first flatus [mean difference (MD) = -2.03, 95%CI = -3.89 to -0.17, P = 0.03], less time to bowel movement (MD = -1.08, 95%CI = -1.60 to -0.57, P < 0.01) and shorter postoperative hospital stays (MD = -1.99, 95%CI = -3.27 to -0.71, P < 0.01) than the non-ERAS group.



WJCC | https://www.wjgnet.com

#### CONCLUSION

ERAS was effective for the quicker recovery in IBD surgery and did not lead to increased complications.

Key Words: Enhanced recovery after surgery; Inflammatory bowel disease; Meta-analysis

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** The purpose of this meta-analysis was to evaluate the safety and efficacy of enhanced recovery after surgery in inflammatory bowel disease surgery. In conclusion, enhanced recovery after surgery was effective for the quicker recovery in inflammatory bowel disease surgery and did not lead to increased complications.

Citation: Peng D, Cheng YX, Tao W, Tang H, Ji GY. Effect of enhanced recovery after surgery on inflammatory bowel disease surgery: A meta-analysis. *World J Clin Cases* 2022; 10(11): 3426-3435 URL: https://www.wjgnet.com/2307-8960/full/v10/i11/3426.htm DOI: https://dx.doi.org/10.12998/wjcc.v10.i11.3426

#### INTRODUCTION

Enhanced recovery after surgery (ERAS) or fast-track surgery programs were first proposed by Kehlet [1], and the purpose of ERAS was to reduce surgical pressure and accelerate postoperative functional recovery[2]. The ERAS protocol involves a series of interventions during the perioperative period, including preoperative short fasting, intraoperative epidural anesthesia, minimally invasive surgery, postoperative pain management and nutritional care[3-5]. Due to its significant advantages and safety, ERAS has developed rapidly over the past decade[6]. In recent years, ERAS has been applied to various surgical fields, including gastrectomy[7], cardiac surgery[8], esophageal cancer surgery and colorectal surgery[9,10].

Although the application of biologics in treating inflammatory bowel disease has changed treatment strategies, most patients with inflammatory bowel disease (IBD) still require surgery[11,12]. IBD patients are often malnourished and immunosuppressed, which increases the risk of postoperative complications and prolongs the postoperative hospital stay[13]. In addition, reoperation was required in a large population of IBD patients, which might not be suitable for minimally invasive surgery[14]. Furthermore, patients with IBD might experience prolonged postoperative intestinal obstruction due to chronic inflammation of the intestinal wall[15]. Therefore, the application of ERAS in IBD surgery might be limited in these high-risk situations.

A few studies suggest the feasibility of ERAS for IBD patients[16]; however, work comparing the efficiency of ERAS in IBD and non-IBD patients is scant[17]. Therefore, the purpose of this meta-analysis was to evaluate the safety and efficacy of ERAS in IBD surgery.

#### MATERIALS AND METHODS

This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement[18]. The PROSPERO registration ID is CRD42021238052, and the link is as follows: https://www.crd.york.ac.uk/prospero/display\_record. php?ID=CRD42021238052.

#### Literature search strategy

The PubMed, EMBASE and Cochrane Library databases were searched by two authors independently. The literature search was conducted on March 21, 2021. The search strategy focused on two key words: ERAS and IBD. The search strategy for ERAS was as follows: "enhanced recovery protocol" OR "enhanced recovery after surgery" OR "enhanced recovery" OR "fast track surgery" OR "fast track rehabilitation" OR "fast track" OR "FTS" OR "ERAS". The search strategy for IBD was as follows: "inflammatory bowel disease" OR "Crohn's" OR "Crohn disease" OR "Crohn's disease" OR "ulcerative colitis" OR "colitis" OR "IBD" OR "CD" OR "UC". Then, we used "AND" to combine these two search strategies, and the publication language was restricted to English in this search.

WJCC https://www.wjgnet.com

#### Inclusion and exclusion criteria

The inclusion criteria were as follows: 1, patients who underwent surgery for CD or UC; 2, the ERAS and non-ERAS protocols were both reported; and 3, reported at least one of the surgical outcomes, including operation time, complications, time to first flatus, time to bowel movement, postoperative hospital stay and readmission. The exclusion criteria were as follows: 1, reviews, letters, case reports, comments or conferences; and 2, publications with insufficient data that could not be extracted. For studies with overlapping patient groups, the most recent study or the study with the larger sample size were included. Disagreement regarding inclusion and exclusion were resolved by discussion between the two authors.

#### Study selection

The databases were searched by the two authors. First, the titles and abstracts were screened for relevant studies. Second, the full texts were evaluated based on the inclusion and exclusion criteria. Disagreements were discussed, and a final judgment was made by a third author if disagreement occurred.

#### Data extraction

The data were extracted and cross-checked by two authors. The extracted data included first author, study date, study design, country, publishing year, patients' baseline information, sample size, operation time, complications, time to first flatus, time to bowel movement, postoperative hospital stay and readmission.

#### Outcomes

The primary outcome of the current meta-analysis was postoperative complications, which were graded based on the Clavien-Dindo classification [19]. Secondary outcomes included operation time, time to first flatus, time to bowel movement, postoperative hospital stays and readmission.

#### Quality assessment

The Newcastle-Ottawa Scale was used to evaluate the quality of the included studies[20]. High-quality studies are indicated by a score of 9 points, medium-quality studies have scores from 7-8 points, and low-quality studies have scores less than 7 points[21].

#### Statistical analysis

In the current meta-analysis, continuous variables are presented as the mean ± standard deviation, and categorical variables are presented as proportions. For dichotomous and continuous variables, odds ratios (ORs) and mean differences (MDs) were calculated, and 95% confidence intervals (CIs) were calculated. The  $l^2$  value and the results of the chi-squared test were used to assess the statistical heterogeneity [22,23]. High heterogeneity was considered when  $l^2 > 50\%$ ; in such cases, the random effects model was used, and P < 0.1 was considered statistically significant. The fixed effects model was used when  $l^2 \le 50\%$ , and P < 0.05 was considered statistically significant. This meta-analysis was performed with RevMan 5.3 (The Cochrane Collaboration, London, United Kingdom).

#### RESULTS

#### Study selection

A total of 602 studies (138 studies in PubMed, 332 studies in EMBASE and 132 studies in the Cochrane Library) were retrieved in the initial search, and 483 studies were screened after excluding duplicated records. The titles and abstracts were screened, and then, 52 studies were left for full-text assessment. Finally, a total of eight studies [16,24-30] that compared the surgical outcomes of IBD patients between ERAS and non-ERAS protocols were included (Figure 1).

#### Patient characteristics and quality assessment of the included studies

A total of eight studies including 1939 patients were included in this meta-analysis. The publication years ranged from 2012- 2021, and the study dates ranged from 2000-2019. There were six retrospective studies, one observational study and one randomized controlled trial (RCT). Three studies were conducted in United States, two studies were conducted in Italy, one study was conducted in China, one study was conducted in France and one study was conducted in the United Kingdom. The sample size and the scores of the Newcastle-Ottawa Scale of each study are shown in Table 1.


#### Baseline information

The baseline information, including age, sex, body mass index, American Society of Anesthesia and surgical methods, was pooled, and no differences were found between the ERAS group and the non-



Table 1 Characteristics of the studies included in the meta-analysis								
Ref.	Year	Study date	Study design	Single/Multi center	Disease type	Country	Sample size	NOS
Spinelli et al[24]	2012	January 2008 to September 2011	Retrospective	Multi center	CD	Italy	90	7
Mineccia et al[25]	2020	May 2007 to December 2018	Observational	Single center	CD	Italy	94	8
Liska et al[ <mark>26</mark> ]	2019	January 2015 to April 2017	Retrospective	Single center	CD and UC	United States	671	8
D'Andrea <i>et al</i> [27]	2020	January 2013 to December 2018	Retrospective	Single center	CD and UC	United States	753	8
Zhu et al <mark>[28</mark> ]	2018	December 2015 to December 2016	RCT	Single center	CD	China	32	8
Vrecenak <i>et al</i> [ <mark>29</mark> ]	2014	December 2000 to December 2010	Retrospective	Single center	CD	United States	71	7
West <i>et al</i> [30]	2013	January 2005 to January 2011	Retrospective	Multi center	CD and UC	United Kingdom	68	8
Meunier <i>et al</i> [16]	2021	November 2015 to December 2019	Retrospective	Multi center	Unknown	France	160	8

CD: Crohn's disease; RCT: Randomized controlled trial; UC: Ulcerative colitis; NOS: Newcastle-Ottawa scale.



**DOI:** 10.12998/wjcc.v10.i11.3426 **Copyright** © The Author(s) 2022.

#### Figure 1 Flowchart of study selection.

ERAS group. The summary meta-analysis of baseline information in each study is shown in Table 2.

#### Complications

Data regarding overall complications were extracted from the eight studies. After pooling all of the data, no significance was found between the ERAS group and the non-ERAS group (OR = 0.82, 95% CI = 0.66 to 1.02, P = 0.08) (Figure 2). To analyze differences in minor and major complications, we conducted subgroup analysis. However, there were no significant differences between the ERAS group and the non-ERAS group in terms of minor complications (OR = 1.13, 95%CI = 0.83 to 1.55, P = 0.43) (Figure 3A) or major complications (OR = 0.64, 95% CI = 0.34 to 1.20, P = 0.16) (Figure 3B).

Baishidena® WJCC | https://www.wjgnet.com

Table 2 Summary of chara	cteristics bet	ween enhanced recovery after surg	ery group and non-enhanced recovery al	ter surgery group
Characteristics	Studies	Participants, ERAS/Non-ERAS	Odds ratio/mean difference (95%CI)	Heterogeneity
Baseline information				
Age, yr	2	256/587	0.35 (-1.72, 2.78); <i>P</i> = 0.65	$I^2 = 0\%; P = 0.59$
Male	7	644/1135	1.20 (0.98, 1.46); <i>P</i> = 0.08	$I^2 = 0\%; P = 0.74$
BMI, kg/m <sup>2</sup>	3	272/603	-0.56 (-1.19, 0.06); $P = 0.08$	$I^2 = 12\%; P = 0.32$
ASA 1-2	4	549/1059	0.91 (0.73, 1.14); <i>P</i> = 0.41	$I^2 = 0\%; P = 0.77$
ASA 3-4	4	510/1059	1.10 (0.88, 1.37); <i>P</i> = 0.41	$I^2 = 0\%; P = 0.77$
Laparoscopic surgery	4	563/1023	1.47 (0.90, 2.38); <i>P</i> = 0.12	$I^2 = 62\%; P = 0.05$
Open surgery	4	460/1023	0.68 (0.42, 1.11); <i>P</i> = 0.12	$I^2 = 62\%; P = 0.05$
Surgical outcomes				
Operation time	2	256/587	-0.17 (-23.45, 23.10); <i>P</i> = 0.99	$I^2 = 78\%; P = 0.03$
Time to first flatus	2	36/86	-2.03 (-3.89, -0.17); $P = 0.03$	$I^2=94\%;P<0.01$
Time to bowel movement	3	81/112	-1.08 (-1.60, -0.57); $P < 0.01$	$I^2 = 71\%; P = 0.03$
Post-operative hospital stay	4	317/629	-1.99 (-3.27, -0.71); $P < 0.01$	$I^2 = 89\%;  P < 0.01$
Anastomotic fistula	6	639/1200	0.36 (0.13, 0.95); <i>P</i> = 0.04	$I^2 = 0\%; P = 0.70$
Bleeding	4	358/568	1.16 (0.48, 2.76); <i>P</i> = 0.75	$I^2 = 0\%; P = 0.80$
Readmission rate	7	673/1234	0.72 (0.51, 1.00); <i>P</i> = 0.05	$I^2 = 0\%; P = 0.87$

ASA: American Association of Anesthesiologists; BMI: Body mass index; CI: Confidence interval; ERAS: Enhanced recovery after surgery.




Figure 2 Comparison of postoperative overall complications between the enhanced recovery after surgery group and the non-enhanced recovery after surgery group. CI: Confidence interval; ERAS: Enhanced recovery after surgery.


#### Other surgical outcomes

Other surgical outcomes were compared between the two groups as well. After pooling all of the data, the ERAS group had less time to first flatus (MD = -2.03, 95%CI = -3.89 to -0.17, P = 0.03), less time to bowel movement (MD = -1.08, 95%CI = -1.60 to -0.57, P < 0.01), less anastomotic fistula (OR = 0.36, 95%CI = 0.13 to 0.95, P = 0.04) and less postoperative hospital stay (MD = -1.99, 95%CI = -3.27 to -0.71, P < 0.01) than the non-ERAS group. However, no significant difference was found in operation time (MD = -0.17, 95%CI = -23.45 to 23.10, P = 0.99), bleeding (OR = 1.16, 95%CI = 0.48 to 2.76, P = 0.75) or readmission rate (OR = 0.72, 95%CI = 0.51 to 1.00, P = 0.05) (Table 2).

#### Publication bias


Repeated meta-analysis was performed by excluding one study at a time, and the exclusion of any one study did not significantly alter the results. Publication bias for the included studies was based on a visual inspection of the funnel plot. The funnel plot was symmetrical, and no obvious publication bias was found (Figure 4).






DOI: 10.12998/wjcc.v10.i11.3426 Copyright © The Author(s) 2022.

Figure 3 Subgroup analysis of minor and major complications between the enhanced recovery after surgery group and the nonenhanced recovery after surgery group. A: Minor complications; B: Major complications. CI: Confidence interval; ERAS: Enhanced recovery after surgery.





#### DISCUSSION

A total of eight studies with 1939 patients were included in this meta-analysis. There were no differences between the ERAS group and the non-ERAS group regarding baseline information. After pooling all of the data, no significance was found between the ERAS group and the non-ERAS group in terms of postoperative complications. However, the ERAS group had a lower prevalence of anastomotic fistula, less time to first flatus, less time to bowel movement and shorter postoperative hospital stays than the non-ERAS group.

IBD patients were at a higher risk of complications due to frequent malnutrition, immunosuppression, intra-abdominal abscess, anemia, fistula and intestinal obstruction than patients without IBD [27]. IBD patients who underwent surgery were more likely to have longer hospital stay, increased postoperative wound infections and higher readmission rates[15,31]. Furthermore, a longer pain relief time and a higher incidence of postoperative intestinal obstruction occurred in IBD patients[15]. Therefore, the ERAS protocol seemed to be a challenging task in IBD patients.

WJCC | https://www.wjgnet.com

In this meta-analysis, we observed that no significance was found between the ERAS group and the non-ERAS group in terms of postoperative complications, and the results were similar to those of previous studies[24-26]. ERAS did not increase the complications after IBD surgery, so ERAS was considered a safe protocol. On the other hand, the ERAS group had a lower likelihood of anastomotic fistula, less time to first flatus, less time to bowel movement and shorter postoperative hospital stays than the non-ERAS group. ERAS might be an effective protocol after IBD surgery. The reduction in hospital stay brings cost savings and reduces the lost work time of family members, improves patient comfort and reduces exposure to hospital-acquired infections at the same time[17]. Moreover, the likelihood anastomotic fistula was significantly reduced in the ERAS group, which confirmed the safety of the ERAS protocol.

A reduction in hospital expenses in ERAS has been reported in other surgeries, including gastric cancer<sup>[7]</sup>, colorectal cancer and esophagus cancer<sup>[9,10]</sup>. A previous study reported a reduction in hospital expenses; however, the number of studies was not sufficient to be included in this metaanalysis<sup>[28]</sup>. There was a lack of analgesic use, which required more follow-up studies confirming the beneficial details of ERAS.

A recent study reported that cancer patients undergoing laparoscopic surgery and ERAS treatment might have an immunological advantage[32]. Although no present studies evaluated the immune status of IBD patients undergoing the ERAS protocol, it is interesting to see whether similar benefits could be observed in the future. The success of ERAS depended on the patient's compliance and motivation, and this was important for IBD patients, who were mostly young and often had an active lifestyle[33,34]. Such preferred patients require rapid recovery in order to return to work and social activities quickly. It was also important to involve the patient's caregivers, as they could play an important role in identifying any signs and symptoms after the patient was discharged<sup>[24]</sup>.

There were some certain limitations in the current meta-analysis. First, only eight studies (one RCT and seven non-RCTs) were included. Second, the number of subgroup analyses of time to first flatus, time to bowel movement, operation time and postoperative hospital stay were relatively small, therefore, the results were not robust, and larger studies are needed. Third, differences might occur between primary or recurrent IBD patients who underwent surgery, and furthermore, the outcomes might differ from CD and UC. Fourth, the use of steroids and biologics might affect the surgical outcomes. Therefore, multicenter, multiregional, prospective and high-quality RCTs should be carried out in the future.

#### CONCLUSION

In conclusion, ERAS was effective for the quicker recovery in IBD surgery and did not lead to increased complications.

#### ARTICLE HIGHLIGHTS

#### Research background

To reduce surgical pressure and accelerate postoperative functional recovery, enhanced recovery after surgery (ERAS) has been recommended. Although the application of biologics in treating inflammatory bowel disease has changed treatment strategies, most patients with inflammatory bowel disease (IBD) still require surgery.

#### Research motivation

Many patients with IBD require surgery. The motivation of this meta-analysis was to examine the effect of ERAS in IBD surgery.

#### Research objectives

The aim of this meta-analysis was to evaluate the advantage of ERAS in IBD surgery.

#### Research methods

The PubMed, EMBASE and Cochrane Library databases were searched from inception to March 21, 2021 to find eligible studies. The primary outcome was the postoperative complications. The secondary outcomes included operation time, time to first flatus, time to bowel movement, postoperative hospital stay and readmission.

#### Research results

A total of eight studies involving 1939 patients were included in this meta-analysis. There was no difference in baseline information between the ERAS group and the non-ERAS group. No significant



difference was found between the ERAS group and the non-ERAS group in terms of postoperative overall complications. The ERAS group had a lower prevalence of anastomotic fistula, less time to first flatus, less time to bowel movement and shorter postoperative hospital stays than the non-ERAS group.

#### Research conclusions

ERAS was effective for the quicker recovery in IBD surgery and did not lead to increased complications.

#### Research perspectives

This meta-analysis provided a preliminary conclusion on the effect of ERAS in IBD surgery. Therefore, multicenter, multiregional, prospective and high-quality randomized controlled trials should be carried out in the future.

#### FOOTNOTES

Author contributions: Tang H and Ji GY are co-corresponding authors; Peng D, Tang H and Ji GY contributed to the quality assessments; Cheng YX and Tao W contributed to data extraction; Peng D, Tao W and Cheng YX contributed to data analysis; Peng D contributed to writing the original draft; Peng D, Tang H and Ji GY contributed to writing and editing; All authors read and approved the final manuscript.

Conflict-of-interest statement: The authors declare that they have no competing interests.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

#### Country/Territory of origin: China

ORCID number: Dong Peng 0000-0003-4050-4337; Yu-Xi Cheng 0000-0002-9220-7855; Wei Tao 0000-0002-3149-0642; Hua Tang 0000-0001-5068-1391; Guang-Yan Ji 0000-0003-4088-9636.

S-Editor: Ma YJ L-Editor: Filipodia P-Editor: Ma YJ

#### REFERENCES

- Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth 1997; 78: 606-1 617 [PMID: 9175983 DOI: 10.1093/bja/78.5.606]
- 2 Wilmore DW, Kehlet H. Management of patients in fast track surgery. BMJ 2001; 322: 473-476 [PMID: 11222424 DOI: 10.1136/bmj.322.7284.473]
- 3 Lassen K, Soop M, Nygren J, Cox PB, Hendry PO, Spies C, von Meyenfeldt MF, Fearon KC, Revhaug A, Norderval S, Ljungqvist O, Lobo DN, Dejong CH; Enhanced Recovery After Surgery (ERAS) Group. Consensus review of optimal perioperative care in colorectal surgery: Enhanced Recovery After Surgery (ERAS) Group recommendations. Arch Surg 2009; 144: 961-969 [PMID: 19841366 DOI: 10.1001/archsurg.2009.170]
- 4 Kehlet H. Fast-track colonic surgery: status and perspectives. Recent Results Cancer Res 2005; 165: 8-13 [PMID: 15865015 DOI: 10.1007/3-540-27449-9\_2]
- 5 Ramírez JM, Blasco JA, Roig JV, Maeso-Martínez S, Casal JE, Esteban F, Lic DC; Spanish working group on fast track surgery. Enhanced recovery in colorectal surgery: a multicentre study. BMC Surg 2011; 11: 9 [PMID: 21489315 DOI: 10.1186/1471-2482-11-9]
- 6 Kehlet H, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. Ann Surg 2008; 248: 189-198 [PMID: 18650627 DOI: 10.1097/SLA.0b013e31817f2c1a]
- Wang LH, Zhu RF, Gao C, Wang SL, Shen LZ. Application of enhanced recovery after gastric cancer surgery: An updated meta-analysis. World J Gastroenterol 2018; 24: 1562-1578 [PMID: 29662294 DOI: 10.3748/wjg.v24.i14.1562]
- Jawahar K, Scarisbrick AA. Parental perceptions in pediatric cardiac fast-track surgery. AORN J 2009; 89: 725-731 [PMID: 19348820 DOI: 10.1016/j.aorn.2008.11.029]
- Triantafyllou T, Olson MT, Theodorou D, Schizas D, Singhal S. Enhanced recovery pathways vs standard care pathways in esophageal cancer surgery: systematic review and meta-analysis. Esophagus 2020; 17: 100-112 [PMID: 31974853 DOI: 10.1007/s10388-020-00718-9]
- 10 Ni X, Jia D, Chen Y, Wang L, Suo J. Is the Enhanced Recovery After Surgery (ERAS) Program Effective and Safe in



Laparoscopic Colorectal Cancer Surgery? J Gastrointest Surg 2019; 23: 1502-1512 [PMID: 30859422 DOI: 10.1007/s11605-019-04170-8]

11 Milsom JW. Laparoscopic surgery in the treatment of Crohn's disease. Surg Clin North Am 2005; 85: 25-34; vii [PMID: 15619526 DOI: 10.1016/j.suc.2004.10.002]

- 12 Sokol H, Seksik P, Cosnes J. Complications and surgery in the inflammatory bowel diseases biological era. Curr Opin Gastroenterol 2014; 30: 378-384 [PMID: 24840000 DOI: 10.1097/MOG.000000000000078]
- Sica GS, Biancone L. Surgery for inflammatory bowel disease in the era of laparoscopy. World J Gastroenterol 2013; 19: 13 2445-2448 [PMID: 23674844 DOI: 10.3748/wjg.v19.i16.2445]
- Aytac E, Stocchi L, Remzi FH, Kiran RP. Is laparoscopic surgery for recurrent Crohn's disease beneficial in patients with 14 previous primary resection through midline laparotomy? Surg Endosc 2012; 26: 3552-3556 [PMID: 22648125 DOI: 10.1007/s00464-012-2361-x
- Dai X, Ge X, Yang J, Zhang T, Xie T, Gao W, Gong J, Zhu W. Increased incidence of prolonged ileus after colectomy for 15 inflammatory bowel diseases under ERAS protocol: a cohort analysis. J Surg Res 2017; 212: 86-93 [PMID: 28550927 DOI: 10.1016/j.jss.2016.12.031]
- 16 Meunier A, Sorce G, Hardy PY, Coimbra C, Decker E, Joris J. Comparison of outcome after right colectomy with an enhanced recovery programme in patients with inflammatory bowel disease and patients operated on for other conditions: a monocentric retrospective study. Int J Colorectal Dis 2021; 36: 757-763 [PMID: 33423143 DOI: 10.1007/s00384-020-03830-5]
- 17 Grass F, Zhu E, Brunel C, Hübner M, Schoepfer A, Demartines N, Hahnloser D. Crohn's versus Cancer: Comparison of Functional and Surgical Outcomes after Right-Sided Resections. Dig Dis 2021; 39: 106-112 [PMID: 32599599 DOI: 10.1159/000509748
- 18 McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; and the PRISMA-DTA Group, Clifford T, Cohen JF, Deeks JJ, Gatsonis C, Hooft L, Hunt HA, Hyde CJ, Korevaar DA, Leeflang MMG, Macaskill P, Reitsma JB, Rodin R, Rutjes AWS, Salameh JP, Stevens A, Takwoingi Y, Tonelli M, Weeks L, Whiting P, Willis BH. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA 2018; 319: 388-396 [PMID: 29362800 DOI: 10.1001/jama.2017.19163]
- 19 Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213 [PMID: 15273542 DOI: 10.1097/01.sla.0000133083.54934.ae]
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-605 [PMID: 20652370 DOI: 10.1007/s10654-010-9491-z]
- 21 Wells GA, Shea BJ, O'Connell D, Peterson J, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2011. [cited November 1, 2011] Available from: https://www.researchgate.net/publication/261773681\_The\_Newcastle-Ottawa Scale NOS for Assessing the Quality of Non-Randomized Studies in Meta-Analysis
- 22 Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract 2008; 14: 951-957 [PMID: 19018930 DOI: 10.1111/j.1365-2753.2008.00986.x]
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560 23 [PMID: 12958120 DOI: 10.1136/bmj.327.7414.557]
- 24 Spinelli A, Bazzi P, Sacchi M, Danese S, Fiorino G, Malesci A, Gentilini L, Poggioli G, Montorsi M. Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease: a case-matched analysis. J Gastrointest Surg 2013; 17: 126-32; discussion p.132 [PMID: 22948838 DOI: 10.1007/s11605-012-2012-5]
- 25 Mineccia M, Menonna F, Germani P, Gentile V, Massucco P, Rocca R, Ferrero A. A retrospective study on efficacy of the ERAS protocol in patients undergoing surgery for Crohn disease: A propensity score analysis. Dig Liver Dis 2020; 52: 625-629 [PMID: 32085992 DOI: 10.1016/j.dld.2020.01.006]
- 26 Liska D, Bora Cengiz T, Novello M, Aiello A, Stocchi L, Hull TL, Steele SR, Delaney CP, Holubar SD. Do Patients With Inflammatory Bowel Disease Benefit from an Enhanced Recovery Pathway? Inflamm Bowel Dis 2020; 26: 476-483 [PMID: 31372647 DOI: 10.1093/ibd/izz172]
- 27 D'Andrea AP, Khetan P, Miller R, Sylla P, Divino CM. Outcomes After Bowel Resection for Inflammatory Bowel Disease in the Era of Surgical Care Bundles and Enhanced Recovery. J Gastrointest Surg 2020; 24: 123-131 [PMID: 31468328 DOI: 10.1007/s11605-019-04362-2]
- 28 Zhu Y, Xiang J, Liu W, Cao Q, Zhou W. Laparoscopy Combined with Enhanced Recovery Pathway in Ileocecal Resection for Crohn's Disease: A Randomized Study. Gastroenterol Res Pract 2018; 2018: 9648674 [PMID: 30534152 DOI: 10.1155/2018/9648674]
- Vrecenak JD, Mattei P. Fast-track management is safe and effective after bowel resection in children with Crohn's disease. 29 J Pediatr Surg 2014; 49: 99-102; discussion 102 [PMID: 24439590 DOI: 10.1016/j.jpedsurg.2013.09.038]
- 30 West MA, Horwood JF, Staves S, Jones C, Goulden MR, Minford J, Lamont G, Baillie CT, Rooney PS. Potential benefits of fast-track concepts in paediatric colorectal surgery. J Pediatr Surg 2013; 48: 1924-1930 [PMID: 24074669 DOI: 10.1016/j.jpedsurg.2013.02.063]
- Ban KA, Berian JR, Liu JB, Ko CY, Feldman LS, Thacker JKM. Effect of Diagnosis on Outcomes in the Setting of 31 Enhanced Recovery Protocols. Dis Colon Rectum 2018; 61: 847-853 [PMID: 29878952 DOI: 10.1097/DCR.00000000001102
- Veenhof AA, Vlug MS, van der Pas MH, Sietses C, van der Peet DL, de Lange-de Klerk ES, Bonjer HJ, Bemelman WA, 32 Cuesta MA. Surgical stress response and postoperative immune function after laparoscopy or open surgery with fast track or standard perioperative care: a randomized trial. Ann Surg 2012; 255: 216-221 [PMID: 22241289 DOI: 10.1097/SLA.0b013e31824336e2
- Feroci F, Kröning KC, Lenzi E, Moraldi L, Borrelli A, Scatizzi M. [The development of a fast track surgery program after 33 laparoscopic colonic surgery in a General Surgery Unit]. Minerva Chir 2010; 65: 127-136 [PMID: 20548268]
- 34 Ahmed J, Khan S, Lim M, Chandrasekaran TV, MacFie J. Enhanced recovery after surgery protocols - compliance and



variations in practice during routine colorectal surgery. Colorectal Dis 2012; 14: 1045-1051 [PMID: 21985180 DOI: 10.1111/j.1463-1318.2011.02856.x]





## Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

